A new type of cancer-killing molecule, not previously described

All medical research, especially cancer research, has two simultaneous visions: The first is to make new and unexpected discoveries that creates new knowledge about conditions regarding life and health. The second is to reveal how diseases arise, what interrupts normal body functions and how cancer can cause the extensive damages that affect seriously ill patients.

The two visions within cancer research coincides in HAMLET

The two visions coincides in Hamlet. The discovery of HAMLET identified a new type of cancer-killing molecule, which has not previously been described. Many properties of HAMLET are unexpected and challenging: the protein´s changed structure and the presence of a oleic acid, the broad effect against many kinds of tumor cells and the high degree of selectivity for tumor cells. At the same time these properties make HAMLET to a new drug candidate, that so far has shown high efficacy in clinical studies and animal models. HAMLET has so far shown no side effects and the substance could be produced with a relatively simple production method.

HAMLET can therefore be the type of drug that is needed to better treat cancer patients. Despite the progress in cancer care, the need for new drugs remains very large and biologicals with cancer-killing effects start to become increasingly common.

Two natural molecules

HAMLET is a biological substance formed by two molecules naturally present in breast milk. Molecules that are naturally present in humans is usually called GRAS (Generally Regarded As Safe).

The substance is extracted from human breast milk and has shown to be effective against a variety of tumor cells. The substance, which kills cancer cells without harming healthy cells, has shown impressive results in both animal models and in trials on humans. As HAMLET is based on natural and endogenous molecules, it is likely that the substance as such does not generate any toxic effects and by that the side effects that has become generally accepted as being a part of the cancer treatments that are available today.


HAMLET effectively kills tumor cells but has also proven to be safe in the proof-of-concept studies done on humans. The compound has demonstrated therapeutic effect on skin papillomas in a placebo-controlled clinical trial. HAMLET resulted in rapid shedding of dead tumor cells and a decrease in tumor size in patients with bladder cancer. Therapeutic effects have also been demonstrated in several studies performed in animal models, including effect against glioblastoma (brain cancer), bladder cancer, and colon cancer.

HAMLET (red) binds to a cancer cell marker (green) which provides a yellow color.

Trials on both animals and humans

Studies have been made both in animals and in humans, indicating that HAMLET could have an effect on a number of common cancers but also on less frequent and hard cured tumor types such as glioblastoma, a form of brain tumor that usually strike relatively young people.

Phase II trials: colon and bladder cancer

Hamlet Pharma plans to conduct Phase II studies on colon cancer and bladder cancer, common and hard cured cancers. The goal with the studies is to create a basis for further development of HAMLET to a registered drug, which may require collaboration with major pharmaceutical companies.

Effective treatment missing

Colon cancer is one of the most common cancers in the world with few treatment alternatives and where patients have a relatively poor prognosis.

Bladder cancer, which is the sixth most common cancer in Sweden, also lacks modern and effective treatment, giving space for the new type of tumor-specific cancer treatment that HAMLET could be.

P43.   Brisuda A, Ho JCS, Kandiyal PS, Ng JTY, Ambite I, Butler DSC, Háček J, Wan MLY, Hien Tran T, Nadeem A, Hiep Tran T, Hastings A, Storm P, Fortunati DL, Esmaeili P, Novotna H, Horňák J, Mu YG, Mok KH, Babjuk M and Svanborg C. 2021. A novel, peptide-based approach for targeting and killing tumor cells with greater precision. Nat Comm.

P42.   Hansen JS, Tran TH, Cavalera M, Paul S, Chaudhuri A, Lindkvist-Petersson K, Ho J and Svanborg C. 2020. Peptide-oleate complexes create novel membrane-bound compartments. Mol Biol Evol 37(11):3083-3093.

P41.   Hien Tran T, Ambite I, Butler D, Wan MLY, Tran HT, Höglund U, Babjuk M and Svanborg C. 2020. Bladder cancer therapy without toxicity – A dose-escalation study of alpha1-oleate. Int J Cancer 147(9):2479–2492.

P40.   Nadeem A, Ho J, Tran, TH, Paul S, Granqvist V, Despretz N and Svanborg C. 2019. Beta-sheet-specific interactions with heat shock proteins define a mechanism of delayed tumor cell death in response to HAMLET. J Mol Biol 431(14): 2612-27.

P39.   Chaudhuri A, Prasanna X, Agiru P, Chakraborty H, Rydström A, Ho JC, Svanborg C, Sengupta D, Chattopadhyay A. 2016. Protein-dependent Membrane Interaction of A Partially Disordered Protein Complex with Oleic Acid: Implications for Cancer Lipidomics. Sci Reports 6:35015.

P38.   Ho CS J., Nadeem A, Rydström A, Puthia M and Svanborg C. 2016. Targeting of nucleotide-binding proteins by HAMLET – a conserved tumor cell death mechanism. Oncogene 35, 897-907.

P37.   Nadeem A, Ho CS J, Sanborn J, Rydström A, Gettel DL, Ngassam VN, Klausen TK, Pedersen SF, Lam M, Parikh AN and Svanborg C. 2015. Protein receptor-independent plasma membrane remodeling by HAMLET; a tumoricidal protein-lipid complex. Sci Reports 5:16432.

P36.    Ho CS J, Sielaff H, Nadeem A, Svanborg C and Gruber G. 2015. The molecular motor F-ATP synthase is targeted by the tumoricidal protein HAMLET. J Mol Biol 427(10):1866-74.

P35.    Ho CS J, Storm P, Rydström A, Bowen B, Alsin F, Sullivan L, Ambite I, Hun Mok K, Northen T and Svanborg C. 2013. Lipids as Tumoricidal Components of Human Alpha-lactalbumin Made Lethal to Tumor Cells (HAMLET); Unique and Shared Effects on Signaling and Death. J Biol Chem doi:10.1074/jbc.M113.468405.

P34.     Storm P, Kjaer Klausen T, Trulsson M, Ho CS J, Dosnon M, Westergren T, Chao YX, Rydstrom A, Yang H, Pedersen SF, Svanborg C .2013. A Unifying Mechanism for Cancer Cell Death through Ion Channel Activation by HAMLET. PLoS ONE 8(3): e58578.

P33.     Xie Y, Min S, Harte NP, Kirk H, O’Brien JE, Voorheis HP, Svanborg C, Hun Mok K. 2013. Electrostatic interactions play an essential role in the binding of oleic acid with α-lactalbumin in the HAMLET-like complex: A study using charge-specific chemical modifications. Proteins 81(1): 1-17.

P32.     Smith K. 2013. Therapy: HAMLET takes a leading role on the colorectal cancer stage. Nat Rev Gastroenterol Hepatol 10:126.

P31.     Puthia M, Storm P, Nadeem A, Hsiung S, Svanborg C. 2014. Prevention and treatment of colon cancer by peroal administration of HAMLET (human α-lactalbumin made lethal to tumour cells). Gut 63: 131-42.

P30.     Ho CS J, Rydstrom A, Manimekalai MSS, Svanborg C, Grüber G. 2012. Low resolution solution structure of HAMLET and the importance of its alpha-domains in tumoricidal activity. PLoS ONE 7(12): e53051.

P29.     Baumann A, Gjerde AU, Ying M, Svanborg C, Holmsen H, Glomm WR, Martinez A, Halskau O. 2012. HAMLET forms annular oligomers when depostited with phospholipid monolayers. J Mol Biol 418(1-2): 90-102.

P28.     P Storm, S Aits, M K Puthia, A Urbano, T Northen, S Powers, B Bowen, Y Chao, W Reindl, D Y Lee, N L Sullivan, J Zhang, M Trulsson, H Yang, J D Watson and C Svanborg. 2011. Conserved features of cancer cells define their sensitivity of HAMLET-induced death; c-Myc and glycolysis. Oncogene 30, 4765–4779.

P27.     Hakansson, A., Roche-Hakansson, H., Mossberg, AK., Svanborg, C. 2011. Apoptosis-like death in bacteria induced by HAMLET, a human milk lipid-protein complex. PLoS ONE 3:e17717.

P26.     Trulsson, M., Yu, H., Gisselsson, L., Chao, Y., Urbano, A., Aits, S., Mossberg, AK, Svanborg, C. 2011. HAMLET binding to α-actinin facilitates tumor cell detachment. PLoS ONE 3:e17179.

P25.     Mossberg, A.-K., Puchades, M., Halskau, O., Baumann, A., Lanekoff, I., Chao, Y., Martinez A., Svanborg, C., Karlsson, R. 2010. HAMLET interacts with lipid membranes and perturbs their structure and integrity. PLoS ONE 2:e9384.

P24.     Mossberg, A.-K., Hou, Y., Svensson, M., Holmqvist, B., Svanborg, C. 2010. HAMLET treatment delays bladder cancer development. J. Urology 183:1590.

P23.     Pettersson-Kastberg J, Mossberg AK, Trulsson M, Yong YJ, Min S, Lim Y, O’Brien JE, Svanborg C, Mok KH. 2009. Alpha-Lactalbumin, engineered to be nonnative and inactive, kills tumor cells when in complex with oleic acid: a new biological function resulting from partial unfolding. J Mol Biol 394(5):994.

P22.     Gustafsson, L., Aits, S., Onnerfjord, P., Trulsson, M., Storm, P., Svanborg, C. 2009. Changes in proteasome structure and function caused by HAMLET in tumor cells. PLoS ONE 4:e5229.

P21.     Aits, S., Gustafsson, L., Hallgren, O., Brest, P., Gustafsson, M., Trulsson, M., Mossberg, A. K., Simon, H.-U., Mograbi, B. and Svanborg, C. 2009. HAMLET (human alpha-lactalbumin made lethal to tumor cells) triggers autophagic tumor cell death. Int J Cancer 124:1008.

P20.     Brest, P., Gustafsson, M., Mossberg, A. K., Gustafsson, L., Duringer, C., Hamiche, A., Svanborg, C. 2007. Histone deacetylase inhibitors promote the tumoricidal effect of HAMLET. Cancer Res 67:11327.

P19.     Mossberg, A. K., Wullt, B., Gustafsson, L., Mansson, W., Ljunggren, E., Svanborg, C. 2007. Bladder cancers respond to intravesical instillation of HAMLET (human alpha-lactalbumin made lethal to tumor cells). Int J Cancer 121:1352.

P18.     Pettersson, J., Mossberg, A.-K., Svanborg. C. 2006. alpha-Lactalbumin species variation, HAMLET formation, and tumor cell death. Biochem Biophys Res Commun 345:260.

P17.     Hallgren, O., Gustafsson, L., Irjala, H., Selivanova, G., Orrenius, S., Svanborg, C. 2006. HAMLET triggers apoptosis but tumor cell death is independent of caspases, Bcl-2 and p53. Apoptosis 11:221.

P16.     Fast, J., Mossberg, A. K., Nilsson, H., Svanborg, C., Akke, M., Linse, S. 2005. Compact oleic acid in HAMLET. FEBS Lett 579:6095.

P15.     Fast, J., Mossberg, A. K., Svanborg, C., Linse, S. 2005. Stability of HAMLET–a kinetically trapped alpha-lactalbumin oleic acid complex. Protein Sci 14:329.

P14.     Gustafsson, L., I. Leijonhufvud, A. Aronsson, A. K. Mossberg, and C. Svanborg. 2004. Treatment of skin papillomas with topical alpha-lactalbumin-oleic acid. N Engl J Med350:2663.

P13.     Baltzer, A., C. Svanborg, and R. Jaggi. 2004. Apoptotic cell death in the lactating mammary gland is enhanced by a folding variant of alpha-lactalbumin. Cell Mol Life Sci61:1221.

P12.     Casbarra, A., L. Birolo, G. Infusini, F. Dal Piaz, M. Svensson, P. Pucci, C. Svanborg, and G. Marino. 2004. Conformational analysis of HAMLET, the folding variant of human alpha-lactalbumin associated with apoptosis. Protein Sci 13:1322.

P11.     Fischer, W., L. Gustafsson, A. K. Mossberg, J. Gronli, S. Mork, R. Bjerkvig, and C. Svanborg. 2004. Human alpha-lactalbumin made lethal to tumor cells (HAMLET) kills human glioblastoma cells in brain xenografts by an apoptosis-like mechanism and prolongs survival. Cancer Res 64:2105.

P10.     Duringer, C., A. Hamiche, L. Gustafsson, H. Kimura, and C. Svanborg. 2003. HAMLET Interacts with Histones and Chromatin in Tumor Cell Nuclei. J Biol Chem 278:42131.

P9.       Svensson, M., J. Fast, A. K. Mossberg, C. Duringer, L. Gustafsson, O. Hallgren, C. L. Brooks, L. Berliner, S. Linse, and C. Svanborg. 2003. Alpha-lactalbumin unfolding is not sufficient to cause apoptosis, but is required for the conversion to HAMLET (human alpha-lactalbumin made lethal to tumor cells). Protein Sci 12:2794.

P8.       Svensson, M., A. K. Mossberg, J. Pettersson, S. Linse, and C. Svanborg. 2003. Lipids as cofactors in protein folding: stereo-specific lipid-protein interactions are required to form HAMLET (human alpha-lactalbumin made lethal to tumor cells). Protein Sci 12:2805.

P7.       Kohler, C., V. Gogvadze, A. Hakansson, C. Svanborg, S. Orrenius, and B. Zhivotovsky. 2001. A folding variant of human alpha-lactalbumin induces mitochondrial permeability transition in isolated mitochondria. Eur J Biochem 268:186.

P6.       Svensson, M., A. Hakansson, A. K. Mossberg, S. Linse, and C. Svanborg. 2000. Conversion of alpha-lactalbumin to a protein inducing apoptosis. Proc Natl Acad Sci USA 97:4221.

P5.       Hakansson, A., M. Svensson, A. K. Mossberg, H. Sabharwal, S. Linse, I. Lazou, B. Lonnerdal, and C. Svanborg. 2000. A folding variant of alpha-lactalbumin with bactericidal activity against Streptococcus pneumoniae. Mol Microbiol 35:589.

P4.       Kohler, C., A. Hakansson, C. Svanborg, S. Orrenius, and B. Zhivotovsky. 1999. Protease activation in apoptosis induced by MAL. Exp Cell Res 249:260.

P3.       Svensson, M., H. Sabharwal, A. Hakansson, A. K. Mossberg, P. Lipniunas, H. Leffler, C. Svanborg, and S. Linse. 1999. Molecular characterization of alpha-lactalbumin folding variants that induce apoptosis in tumor cells. J Biol Chem 274:6388.

P2.       Hakansson, A., J. Andreasson, B. Zhivotovsky, D. Karpman, S. Orrenius, C. Svanborg. 1999. Multimeric alpha-lactalbumin from human milk induces apoptosis through a direct effect on cell nuclei. Exp Cell Res 246:451.

P1.       Hakansson, A., Zhivotovsky, B., Orrenius, S., Sabharwal, H., Svanborg, C. 1995. Apoptosis induced by a human milk protein. Proc Natl Acad Sci USA 92:8064.

R1.       Svensson, M., C. Duringer, O. Hallgren, A. K. Mossberg, A. Hakansson, S. Linse, and C. Svanborg. 2002. Hamlet–a complex from human milk that induces apoptosis in tumor cells but spares healthy cells. Adv Exp Med Biol 503:125.

R2.       Svanborg, C., H. Agerstam, A. Aronson, R. Bjerkvig, C. Duringer, W. Fischer, L. Gustafsson, O. Hallgren, I. Leijonhuvud, S. Linse, A. K. Mossberg, H. Nilsson, J. Pettersson, and M. Svensson. 2003. HAMLET kills tumor cells by an apoptosis-like mechanism–cellular, molecular, and therapeutic aspects. Adv Cancer Res 88:1.

R3.       Duringer, C., Hallgren, O., Gustafsson, L., Pettersson, J., Mossberg, A. K., Manolov, T. and Svanborg, C. 2005. HAMLET; a novel tool to identify apoptotic pathways in tumor cells. in Sluyser, M. (Ed), Application of apoptosis to cancer treatment., Springer, pp. 223-246.

R4.       Gustafsson, L., Hallgren, O., Mossberg, A. K., Pettersson, J., Fischer, W., Aronsson, A. and Svanborg, C. 2005. HAMLET Kills Tumor Cells by Apoptosis: Structure, Cellular Mechanisms, and Therapy. J Nutr 135:1299.

R5.       Mok, K. H., Pettersson, J., Orrenius, S. and Svanborg, C. 2007. HAMLET, protein folding, and tumor cell death. Biochem Biophys Res Commun 354:1.

 R6.       Hallgren, O., Aits, S., Brest, P., Gustafsson, L., Mossberg, A. K., Wullt, B. and Svanborg, C. 2008. Apoptosis and tumor cell death in response to HAMLET (human alpha-lactalbumin made lethal to tumor cells). Adv Exp Med Biol 606:217.

R7.       Pettersson-Kastberg, J., Aits, S., Gustafsson L., Mossberg A., Storm, P., Trulsson, M., Persson, F., Mok, K. H. and Svanborg, C. 2009. Can misfolded proteins be beneficial? The HAMLET case. Ann med 41:162.

R8.       Svanborg, C., Aits, S., Brest, P., Gustafsson, L., Mok, K., Moreillhon, C., Mossberg, A., Pettersson, J., Storm, P. and Trulsson, M. 2009. HAMLET, a tumoricidal molecular complex from human milk. BMC Proceedings 3(Suppl 5):S11

R9.       Mossberg, A. K., Mok, K. H., Morozova-Roche, L. A. and Svanborg, C. 2010. Structure and function of human a-lactalbumin made lethal to tumor cell (HAMLET)-type complexes. FEBS Journal 277:4614.

P10.     Min S, Meehan J, Sullivan LM, Harte NP, Xie Y, Davey GP, Svanborg C, Brodkorb A, Mok KH. (2012) Alternatively folded proteins with unexpected beneficial functions. Biochem Soc Trans. 40(4):746-751.

P11.     Ho CS J, Rydström A, Trulsson M, Bålfors J, Storm P, Puthia M, Nadeem A and Svanborg C. 2012. HAMLET: functional properties and therapeutic potential. Future Oncol. 8(10), 1301-1313.

P12.    Ho JCS, Nadeem A and Svanborg C. 2017. HAMLET – A protein-lipid complex with broad tumoricidal activity. Biochem Biophys Res Commun 482 (3), 454–458.